Downregulation of MiR-133b Predict Progression and Poor Prognosis in Patients with Urothelial Carcinoma of Bladder

Overview

Journal Cancer Med

Specialty Oncology

Date 2016 Jun 14

PMID 27292588

Citations 18

Authors

Xiaonan Chen

Bin Wu

Zhenqun Xu

Shijie Li

Shutao Tan

Xuefeng Liu

Kefeng Wang

Affiliations

Soon will be listed here.

Abstract

We found microRNA-133b (miR-133b) was downregulated in urothelial carcinoma of the bladder (UCB) tissues, and it could inhibit the proliferation and induce apoptosis in UCB cells. Consequently, we intend to explore the clinical significance of miR-133b in UCB patients. Expression of miR-133b in 146 UCB specimens and matched adjacent non-neoplastic bladder tissues were measured by quantitative real-time polymerase chain reaction. The overall survival (OS) curve and progression-free survival (PFS) curve were plotted using the Kaplan-Meier method. Prognostic factors for OS and PFS were identified by univariate and multivariate analyses using the Cox proportional hazards regression model. The expression of miR-133b was significantly downregulated in UCB tissues compared with those in adjacent non-neoplastic bladder tissues (P < 0.001). Among UCB patients, low expression of miR-133b significantly correlated with aggressive clinicopathological features. Multivariate analysis indicated that the expression of miR-133b was the independent prognostic factors for predicting PFS (RR: 2.97; 95% CI: 1.78-6.44; P = 0.009) and OS (RR: 4.23; 95% CI: 1.51-11.8; P = 0.011) in patients with UCB. Our study demonstrated that downregulation of miR-133b associated with aggressive clinicopathological features and predicted unfavorable prognosis in patients with UCB, might serve as feasible biomarker for clinical outcome of UCB patients after surgery and potential therapeutic target in the future.

Citing Articles

Epigenetic Biomarkers as a New Diagnostic Tool in Bladder Cancer-From Early Detection to Prognosis.

Jaszek N, Bogdanowicz A, Siwiec J, Starownik R, Kwasniewski W, Mlak R J Clin Med. 2024; 13(23).

PMID: 39685620 PMC: 11642161. DOI: 10.3390/jcm13237159.

MiR-133b regulates the proliferation, colony formation, and invasion of bladder cancer cells via inhibiting SOX4.

Zhong M, Jiang F, Song L, Nie M, Lan G Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022; 47(4):407-415.

PMID: 35545336 PMC: 10930165. DOI: 10.11817/j.issn.1672-7347.2022.210702.

miR-19a-3p Promotes Tumor-Relevant Behaviors in Bladder Urothelial Carcinoma via Targeting THBS1.

Xu G, Li J, Yu L Comput Math Methods Med. 2021; 2021:2710231.

PMID: 34745323 PMC: 8568512. DOI: 10.1155/2021/2710231.

Emerging Biomarkers for Predicting Bladder Cancer Lymph Node Metastasis.

Zhang C, Hu J, Li H, Ma H, Othmane B, Ren W Front Oncol. 2021; 11:648968.

PMID: 33869048 PMC: 8044933. DOI: 10.3389/fonc.2021.648968.

Identification of the miRNA-mRNA regulatory pathways and a miR-21-5p based nomogram model in clear cell renal cell carcinoma.

Zhao Y, Tao Z, Chen X PeerJ. 2020; 8:e10292.

PMID: 33194441 PMC: 7648458. DOI: 10.7717/peerj.10292.

References

Zhang B, Pan X, Cobb G, Anderson T . microRNAs as oncogenes and tumor suppressors. Dev Biol. 2006; 302(1):1-12. DOI: 10.1016/j.ydbio.2006.08.028. View

Lee T, Chaux A, Karram S, Miyamoto H, Miller J, Fajardo D . Papillary urothelial neoplasm of low malignant potential of the urinary bladder: clinicopathologic and outcome analysis from a single academic center. Hum Pathol. 2011; 42(11):1799-803. DOI: 10.1016/j.humpath.2011.03.006. View

Lv L, Zhou J, Lin C, Hu G, Yi L, Du J . DNA methylation is involved in the aberrant expression of miR-133b in colorectal cancer cells. Oncol Lett. 2015; 10(2):907-912. PMC: 4509424. DOI: 10.3892/ol.2015.3336. View

Chen Z, Liu X, Hu Z, Wang Y, Liu M, Liu X . Identification and characterization of tumor suppressor and oncogenic miRNAs in gastric cancer. Oncol Lett. 2015; 10(1):329-336. PMC: 4487161. DOI: 10.3892/ol.2015.3179. View

Jones T, Cheng L . Papillary urothelial neoplasm of low malignant potential: evolving terminology and concepts. J Urol. 2006; 175(6):1995-2003. DOI: 10.1016/S0022-5347(06)00267-9. View

Zhou Y, Wu D, Tao J, Qu P, Zhou Z, Hou J . MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer. Scand J Urol. 2012; 47(5):423-32. DOI: 10.3109/00365599.2012.748821. View

Wu D, Pan H, Zhou Y, Zhou J, Fan Y, Qu P . microRNA-133b downregulation and inhibition of cell proliferation, migration and invasion by targeting matrix metallopeptidase-9 in renal cell carcinoma. Mol Med Rep. 2014; 9(6):2491-8. DOI: 10.3892/mmr.2014.2116. View

Zhang C, Yao C, Li H, Wang G, He X . Serum levels of microRNA-133b and microRNA-206 expression predict prognosis in patients with osteosarcoma. Int J Clin Exp Pathol. 2014; 7(7):4194-203. PMC: 4129034. View

Rebouissou S, Herault A, Letouze E, Neuzillet Y, Laplanche A, Ofualuka K . CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma. J Pathol. 2012; 227(3):315-24. DOI: 10.1002/path.4017. View

10.

Chen X, Wang K, Xu Z, Li S, Liu Q, Fu D . MiR-133b regulates bladder cancer cell proliferation and apoptosis by targeting Bcl-w and Akt1. Cancer Cell Int. 2014; 14:70. PMC: 4238049. DOI: 10.1186/s12935-014-0070-3. View

11.

Hu G, Chen D, Li X, Yang K, Wang H, Wu W . miR-133b regulates the MET proto-oncogene and inhibits the growth of colorectal cancer cells in vitro and in vivo. Cancer Biol Ther. 2010; 10(2):190-7. DOI: 10.4161/cbt.10.2.12186. View

12.

Akcakaya P, Ekelund S, Kolosenko I, Caramuta S, Ozata D, Xie H . miR-185 and miR-133b deregulation is associated with overall survival and metastasis in colorectal cancer. Int J Oncol. 2011; 39(2):311-8. DOI: 10.3892/ijo.2011.1043. View

13.

Chen G, Peng J, Zhu W, Tao G, Song Y, Zhou X . Combined downregulation of microRNA-133a and microRNA-133b predicts chemosensitivity of patients with esophageal squamous cell carcinoma undergoing paclitaxel-based chemotherapy. Med Oncol. 2014; 31(11):263. DOI: 10.1007/s12032-014-0263-6. View

14.

Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-55. View

15.

Li H, Wang J, Xiao W, Xia D, Lang B, Wang T . Epigenetic inactivation of KLF4 is associated with urothelial cancer progression and early recurrence. J Urol. 2013; 191(2):493-501. DOI: 10.1016/j.juro.2013.08.087. View

16.

Song T, Xia W, Shao N, Zhang X, Wang C, Wu Y . Differential miRNA expression profiles in bladder urothelial carcinomas. Asian Pac J Cancer Prev. 2010; 11(4):905-11. View

17.

Schickel R, Boyerinas B, Park S, Peter M . MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene. 2008; 27(45):5959-74. DOI: 10.1038/onc.2008.274. View

18.

Hara T, Matsuyama H, Kamiryo Y, Hayashida S, Yamamoto N, Nasu T . Use of preoperative performance status and hemoglobin concentration to predict overall survival for patients aged ≥ 75 years after radical cystectomy for treatment of bladder cancer. Int J Clin Oncol. 2015; 21(1):139-47. DOI: 10.1007/s10147-015-0857-9. View

19.

Fujii Y, Kawakami S, Koga F, Nemoto T, Kihara K . Long-term outcome of bladder papillary urothelial neoplasms of low malignant potential. BJU Int. 2003; 92(6):559-62. DOI: 10.1046/j.1464-410x.2003.04415.x. View

20.

Nofech-Mozes R, Khella H, Scorilas A, Youssef L, Krylov S, Lianidou E . MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma. Cancer Med. 2016; 5(4):656-64. PMC: 4831284. DOI: 10.1002/cam4.631. View